Clinical trialNCT07638722Not, yet, recruitingPhase 2Interventional

Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With Treatment

SponsorSWOG Cancer Research NetworkEnrollment138Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueRecurrent Nodal Marginal Zone LymphomaRecurrent Splenic Marginal Zone LymphomaRefractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueRefractory Nodal Marginal Zone LymphomaRefractory Splenic Marginal Zone Lymphoma

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Boyu Hu
SWOG Cancer Research Network
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

No facility list is in our current data snapshot for this study. The registry record on ClinicalTrials.gov ↗ carries any published locations. Why? →

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 3 Oct 2026
Primary completion: 31 Jul 2028
Completion: 31 Jul 2029
Last update posted: 10 Jun 2026
Registered enrollment: 138
Registry id: NCT07638722

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.